Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) have been given an average recommendation of “Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $21.00.
Several research analysts have issued reports on ARTV shares. HC Wainwright assumed coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th.
Get Our Latest Stock Report on ARTV
Artiva Biotherapeutics Trading Up 0.4 %
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, equities research analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $623,000. BNP Paribas Financial Markets bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $42,000. MetLife Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter valued at $135,000. Acuta Capital Partners LLC bought a new position in Artiva Biotherapeutics in the 3rd quarter worth $680,000. Finally, RTW Investments LP purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth $2,300,000.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
See Also
- Five stocks we like better than Artiva Biotherapeutics
- How to Short Nasdaq: An Easy-to-Follow Guide
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Consumer Staples Stocks, Explained
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.